Human RCTPubMed ID: 34155184·2021

SURPASS-1: Tirzepatide versus Semaglutide in Type 2 Diabetes

Rosenstock J, Wysham C, Frías JP, et al.

Lancet, 2021 · n = 1879

Key finding

Tirzepatide 15mg reduced HbA1c by 2.3% versus semaglutide 2.4mg by 2.0% (p=0.007); 85% vs 78% achieved A1c <7%.

Summary

Phase 3 head-to-head trial demonstrating tirzepatide superior to semaglutide for glycemic control in type 2 diabetes.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

New England Journal of Medicine · 2024 · Human RCT

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

The Lancet · 2023 · Human RCT

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Nature Medicine · 2023 · Human RCT

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

New England Journal of Medicine · 2023 · Human RCT

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Sleep Medicine Reviews · 2023 · Human Pilot